Fundraising FoxAnelixis Therapeutics
Cambridge, US · Founded 2015 · Delaware corporation · 1 known investors
Find your way into Anelixis Therapeutics
Sign up to see every warm intro you have to Anelixis Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Anelixis Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
KB
Kent BransfordNamed on SEC filing
MM
Maeve McNallyNamed on SEC filing
TR
Theodore ReichNamed on SEC filing
SP
Steven PerrinNamed on SEC filing
PS
Paul SallaberryNamed on SEC filing
AN
Augie NietoNamed on SEC filing
EC
Eric CravenNamed on SEC filing
JH
James HeywoodNamed on SEC filing
Investors · 1
Biotechnology Value FundreportedSan Francisco
How we know: funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$7.9M disclosed across 3 rounds · 2017–2019
▶$1MraisedMay 2019 · 10 investors · BiotechnologyRule 506(b)
▶$1MraisedMay 2019 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Maeve McNallyExecutive Officer
- Steven PerrinExecutive Officer, Director
- Augie NietoDirector
- Walter OgierDirector
- Offering amount
- $6M
- Amount sold
- $1M
- Minimum investment
- $50K
- Sales commissions
- $100K
- Placement agents
- Noble Capital Markets
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$2.6MraisedApr 2018 · 6 investors · BiotechnologyRule 506(b)
▶$2.6MraisedApr 2018 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- WALTER C. OGIERDirector
- AUGIE NIETODirector
- MAEVE MCNALLYExecutive Officer
- STEVEN PERRINExecutive Officer, Director
- Offering amount
- $4.5M
- Amount sold
- $2.6M
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$4.3MraisedJun 2017 · 4 investors · BiotechnologyRule 506(b)
▶$4.3MraisedJun 2017 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kent BransfordDirector
- Maeve McNallyExecutive Officer
- Theodore ReichDirector
- Steven PerrinExecutive Officer, Director
- Paul SallaberryDirector
- Augie NietoDirector
- Eric CravenDirector
- James HeywoodDirector
- Offering amount
- $8M
- Amount sold
- $4.3M
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Anelixis Therapeutics's investors?
- Anelixis Therapeutics's investors include Biotechnology Value Fund.
- How much funding has Anelixis Therapeutics raised?
- Anelixis Therapeutics has disclosed $7.9M raised across 3 rounds.
- Where is Anelixis Therapeutics headquartered?
- Anelixis Therapeutics is headquartered in Cambridge, US.